Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 29681 results found since Jan 2013.
Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells
J Cell Mol Med. 2023 Sep 7. doi: 10.1111/jcmm.17935. Online ahead of print.ABSTRACTMucosal melanoma (MM) is a very rare and aggressive type of cancer for which immunotherapy or targeted therapy such as BRAF/MEK inhibitors, used in cutaneous melanoma, usually fail. Due to our earlier experience showing the high effectiveness of epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) inhibitors in reducing the activation of the MAPK and PI3K/AKT signalling pathways, we aim to test whether these drugs would also be effective for mucosal melanoma. Cells representing two commercially available mucosa...
Source: Molecular Medicine - September 8, 2023 Category: Molecular Biology Authors: Aleksandra Simiczyjew Justyna W ądzyńska Magdalena Kot Marcin Zi ętek Rafa ł Matkowski Mai P Hoang Piotr Donizy Dorota Nowak Source Type: research
Effect of laparoscopic complete mesocolic excision combined with immunotherapy and its impact on immune function and tumor markers in elderly patients with colon cancer
CONCLUSION: Laparoscopic complete mesocolic excision combined with immunotherapy exhibits a superior therapeutic effect to traditional open surgery in elderly patients with colon cancer, and is worthy of clinical promotion.PMID:37680796 | PMC:PMC10480738 | DOI:10.12669/pjms.39.5.7090
Source: Cancer Control - September 8, 2023 Category: Cancer & Oncology Authors: Tao Zhang Qian Lin Zhi Liu Hua Yang Source Type: research
Anti ‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
Int J Oncol. 2023 Nov;63(5):122. doi: 10.3892/ijo.2023.5570. Epub 2023 Sep 8.ABSTRACTImmune checkpoint inhibitors (ICIs) play a significant anti‑tumor role in the management of non‑small cell lung cancer. The most broadly used ICIs are anti‑programmed death 1 (PD‑1), anti‑programmed cell death‑ligand 1, and anti‑cytotoxic T lymphocyte‑associated antigen‑4 monoclonal antibody. Compared with traditional chemotherapy, ICIs have the advantages of greater efficiency and more specific targeting. However, the resulting immune‑related adverse events limit the clinical application of ICIs, especially checkpoint ...
Source: International Journal of Oncology - September 8, 2023 Category: Cancer & Oncology Authors: Xiao Hu Jin Ren Qianfei Xue Rumei Luan Dongyan Ding Jie Tan Xin Su Junling Yang Source Type: research
A review of immune modulators and immunotherapy in infectious diseases
Mol Cell Biochem. 2023 Sep 8. doi: 10.1007/s11010-023-04825-w. Online ahead of print.ABSTRACTThe human immune system responds to harmful foreign invaders frequently encountered by the body and employs defense mechanisms to counteract such assaults. Various exogenous and endogenous factors play a prominent role in maintaining the balanced functioning of the immune system, which can result in immune suppression or immune stimulation. With the advent of different immune-modulatory agents, immune responses can be modulated or regulated to control infections and other health effects. Literature provides evidence on various immu...
Source: Molecular and Cellular Biochemistry - September 8, 2023 Category: Biochemistry Authors: P Sangeetha Vijayan Joseph Xavier Mohanan Parayanthala Valappil Source Type: research
Hsa_circ_0001479 accelerates tumorigenesis of gastric cancer and mediates immune escape
Int Immunopharmacol. 2023 Sep 6;124(Pt A):110887. doi: 10.1016/j.intimp.2023.110887. Online ahead of print.ABSTRACTGastric cancer (GC) is a common fatal malignant tumor of the digestive tract, particularly in Asia. Circular RNA (circRNA) has been proved to regulate malignancy progression and immunotherapeutic efficacy in multiple tumors, including GC. Notably, the function of circRNAs in GC has not been completely revealed. Therefore, exploration of more GC related circRNAs may provide potential strategies for GC treatment. In the study, it was observed that hsa_circ_0001479 exhibited a high level of expression in GC and w...
Source: International Immunopharmacology - September 8, 2023 Category: Allergy & Immunology Authors: Jiayi Zang Lin Xiao Xin Shi Sinan Liu Yan Wang Baolan Sun Shaoqing Ju Ming Cui Rongrong Jing Source Type: research
Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells
J Cell Mol Med. 2023 Sep 7. doi: 10.1111/jcmm.17935. Online ahead of print.ABSTRACTMucosal melanoma (MM) is a very rare and aggressive type of cancer for which immunotherapy or targeted therapy such as BRAF/MEK inhibitors, used in cutaneous melanoma, usually fail. Due to our earlier experience showing the high effectiveness of epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) inhibitors in reducing the activation of the MAPK and PI3K/AKT signalling pathways, we aim to test whether these drugs would also be effective for mucosal melanoma. Cells representing two commercially available mucosa...
Source: J Cell Mol Med - September 8, 2023 Category: Molecular Biology Authors: Aleksandra Simiczyjew Justyna W ądzyńska Magdalena Kot Marcin Zi ętek Rafa ł Matkowski Mai P Hoang Piotr Donizy Dorota Nowak Source Type: research
Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC
CONCLUSIONS: This retrospective real-world population study revealed that CPS differentiated OS better than TPS in patients with advanced NSCLC with ICI monotherapy. Remarkably, this was driven by the performance of the TPS-/CPS+ subgroup, indicating that CPS may be a better predictive biomarker for ICI efficacy.PMID:37681219 | PMC:PMC10480627 | DOI:10.1016/j.jtocrr.2023.100532
Source: Clinical Lung Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Ezgi B Ulas Sayed M S Hashemi Ilias Houda Adem Kaynak Joris D Veltman Marieke F Fransen Teodora Radonic Idris Bahce Source Type: research
Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
Cancer Manag Res. 2023 Sep 1;15:905-911. doi: 10.2147/CMAR.S418116. eCollection 2023.ABSTRACTSmall cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers and is on the rise annually. It is characterized by low differentiation, high malignancy, and rapid growth. Consequently, treatment options are limited, and the patient's prognosis is poor. The emergence of immunotherapy has partially improved the survival and prognosis of SCLC patients. However, a unique response known as "pseudoprogression" during immunotherapy has raised concerns. The occurrence of tumor enlargement despite a positive response to im...
Source: Cell Research - September 8, 2023 Category: Cytology Authors: Wanshan Zhu Lexia Wu Jiaming Wu Sihong Lin Cantu Fang Huatang Zhang Source Type: research
Involvement of CHRNA6 in the Immune Response in Lung Squamous Cell Carcinoma and its Potential as a Drug Target for the Disease
CONCLUSION: CHRNA6 may be associated with immune infiltration in LUSC and affects patient prognosis and immunotherapeutic response by regulating immune cells and immune pathways. In addition, adavosertib may be a potential drug for the treatment of LUSC.PMID:37680128 | DOI:10.2174/1381612829666230901143203
Source: Current Pharmaceutical Design - September 8, 2023 Category: Drugs & Pharmacology Authors: Fengyu Zhang Meidi Zhang Xin Yuan Yulian Tao Ju Wang Source Type: research
Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC
CONCLUSIONS: This retrospective real-world population study revealed that CPS differentiated OS better than TPS in patients with advanced NSCLC with ICI monotherapy. Remarkably, this was driven by the performance of the TPS-/CPS+ subgroup, indicating that CPS may be a better predictive biomarker for ICI efficacy.PMID:37681219 | PMC:PMC10480627 | DOI:10.1016/j.jtocrr.2023.100532
Source: Cell Research - September 8, 2023 Category: Cytology Authors: Ezgi B Ulas Sayed M S Hashemi Ilias Houda Adem Kaynak Joris D Veltman Marieke F Fransen Teodora Radonic Idris Bahce Source Type: research
Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
Cancer Manag Res. 2023 Sep 1;15:905-911. doi: 10.2147/CMAR.S418116. eCollection 2023.ABSTRACTSmall cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers and is on the rise annually. It is characterized by low differentiation, high malignancy, and rapid growth. Consequently, treatment options are limited, and the patient's prognosis is poor. The emergence of immunotherapy has partially improved the survival and prognosis of SCLC patients. However, a unique response known as "pseudoprogression" during immunotherapy has raised concerns. The occurrence of tumor enlargement despite a positive response to im...
Source: Cell Research - September 8, 2023 Category: Cytology Authors: Wanshan Zhu Lexia Wu Jiaming Wu Sihong Lin Cantu Fang Huatang Zhang Source Type: research
A near-infrared fluorescence-enhancing plasmonic biosensing microarray identifies soluble PD-L1 and ICAM-1 as predictive checkpoint biomarkers for cancer immunotherapy
Biosens Bioelectron. 2023 Aug 23;240:115633. doi: 10.1016/j.bios.2023.115633. Online ahead of print.ABSTRACTSensitive and accurate biomarker-driven assay guidance has been widely adopted to identify responsive patients for immune checkpoint blockade (ICB) therapy to impede disease progression and extend survival. However, most current assays are invasive, requiring surgical pathology specimens and only informing monochronic information. Here, we report a multiplexed enhanced fluorescence microarray immunoassay (eFMIA) based on a nanostructured gold nanoisland substrate (AuNIS), which macroscopically amplifies near-infrared...
Source: Biosensors and Bioelectronics - September 8, 2023 Category: Biotechnology Authors: Zhijun Lin Mengyao Liu Wei Xing Fenghua Wang Hongxia Zhang Xiaoli Wei Hans Schmitthenner Xi Xie Xiaojun Xia Jiang Yang Source Type: research
Cyclometalated iridium(III) complexes induce immunogenic cell death in HepG2 cells via paraptosis
Bioorg Chem. 2023 Sep 6;140:106837. doi: 10.1016/j.bioorg.2023.106837. Online ahead of print.ABSTRACTImmunotherapy has been shown to provide superior antitumor efficacy by activating the innate immune system to recognize, attack and eliminate tumor cells without seriously harming normal cells. Herein, we designed and synthesized three new cyclometalated iridium(III) complexes (Ir1, Ir2, Ir3) then evaluated their antitumor activity. When co-incubated with HepG2 cells, the complex Ir1 localized in the lysosome, where it induced paraptosis and endoplasmic reticulum stress (ER stress). Notably, Ir1 also induced immunogenic cel...
Source: Bioorganic Chemistry - September 8, 2023 Category: Chemistry Authors: Jiaxin Liao Yuqing Zhang Minying Huang Zhijun Liang Yao Gong Ben Liu Yuling Li Jiaxi Chen Wei Wu Zunnan Huang Jing Sun Source Type: research
Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma
CONCLUSION: The RMM-I molecular subtype constituted the novel molecular characteristic subtype of LUAD, which complemented the existing pathological typing. More refined and accurate molecular subtypes provide help to reveal the mechanism of LUAD development. In addition, the RMM-I score offers a reliable tool for accurate prognosis of LUAD.PMID:37680151 | DOI:10.2174/0929867331666230901110629
Source: Current Medicinal Chemistry - September 8, 2023 Category: Chemistry Authors: Jiajing Wang Jianfeng Shu Source Type: research
